KR20220063218A - 안정한 농축 방사성 약제학적 조성물 - Google Patents

안정한 농축 방사성 약제학적 조성물 Download PDF

Info

Publication number
KR20220063218A
KR20220063218A KR1020227012069A KR20227012069A KR20220063218A KR 20220063218 A KR20220063218 A KR 20220063218A KR 1020227012069 A KR1020227012069 A KR 1020227012069A KR 20227012069 A KR20227012069 A KR 20227012069A KR 20220063218 A KR20220063218 A KR 20220063218A
Authority
KR
South Korea
Prior art keywords
salt
pharmaceutical composition
acid
ascorbic acid
gentisic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227012069A
Other languages
English (en)
Korean (ko)
Inventor
마우리지오 에페. 마리아니
프란체스카 오를란디
로렌자 푸가자
로렌조 사케티
마티아 테데스코
도나토 바르바토
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20220063218A publication Critical patent/KR20220063218A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020227012069A 2019-09-16 2020-09-15 안정한 농축 방사성 약제학적 조성물 Pending KR20220063218A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19197607 2019-09-16
EP19197607.5 2019-09-16
PCT/EP2020/075767 WO2021052960A1 (en) 2019-09-16 2020-09-15 Stable, concentrated radiopharmaceutical composition

Publications (1)

Publication Number Publication Date
KR20220063218A true KR20220063218A (ko) 2022-05-17

Family

ID=67981980

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227012069A Pending KR20220063218A (ko) 2019-09-16 2020-09-15 안정한 농축 방사성 약제학적 조성물

Country Status (11)

Country Link
US (2) US20220401593A1 (https=)
EP (1) EP4031193A1 (https=)
JP (2) JP7762648B2 (https=)
KR (1) KR20220063218A (https=)
CN (1) CN114728088A (https=)
AR (1) AR119974A1 (https=)
AU (1) AU2020349002B2 (https=)
CA (1) CA3154302A1 (https=)
IL (1) IL291315A (https=)
TW (1) TW202123976A (https=)
WO (1) WO2021052960A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4442285A1 (en) * 2021-11-30 2024-10-09 Nihon Medi-Physics Co., Ltd. Stabilized radiopharmaceutical composition
CN114404618A (zh) * 2022-03-28 2022-04-29 北京先通国际医药科技股份有限公司 放射性药物水溶液及其用途
CN114404619A (zh) * 2022-03-28 2022-04-29 北京先通国际医药科技股份有限公司 放射性药物水溶液及其制备方法和用途
CN116920129A (zh) * 2022-04-02 2023-10-24 北京先通国际医药科技股份有限公司 放射性药物水溶液及其制备方法和用途
JP2026505341A (ja) 2023-02-08 2026-02-13 ノバルティス アーゲー 神経膠芽腫を治療するための方法
IL322257A (en) 2023-02-23 2025-09-01 Novartis Ag Methods of treating breast cancer
CN121793988A (zh) 2023-09-13 2026-04-03 东丽株式会社 癌的治疗、预防和/或诊断用药物组合物
TW202527951A (zh) 2023-12-15 2025-07-16 瑞士商諾華公司 用於治療乳腺癌的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5139678B2 (ja) * 2003-07-24 2013-02-06 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 安定な放射性医薬品組成物およびその製法
WO2008009444A1 (en) 2006-07-19 2008-01-24 Van Dulmen, Adrianus, A. Use of ethanol for stabilizing a single-vial liquid formulation of a radiolabeled peptide
ES2745635T3 (es) 2012-09-25 2020-03-03 Advanced Accelerator Applications Usa Inc Antagonistas de GRPR para la detección, diagnóstico y tratamiento del cáncer positivo para GRPR

Also Published As

Publication number Publication date
AR119974A1 (es) 2022-01-26
EP4031193A1 (en) 2022-07-27
WO2021052960A1 (en) 2021-03-25
US20220401593A1 (en) 2022-12-22
JP2022548875A (ja) 2022-11-22
IL291315A (en) 2022-05-01
CN114728088A (zh) 2022-07-08
TW202123976A (zh) 2021-07-01
US20250332301A1 (en) 2025-10-30
JP2026031934A (ja) 2026-02-25
AU2020349002A1 (en) 2022-04-28
JP7762648B2 (ja) 2025-10-30
AU2020349002B2 (en) 2024-05-02
CA3154302A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
AU2020349002B2 (en) Stable, concentrated radiopharmaceutical composition
TWI878344B (zh) 放射性標記grpr拮抗劑之方法及其套組
JP2023546525A (ja) 前立腺特異的膜抗原を標的とする化合物及びその調製方法と応用
US12605447B2 (en) Stable formulations for radionuclide complexes
CN118647415A (zh) 包含225锕标记的络合物和铋多价螯合剂的药物组合物
KR102840765B1 (ko) 방사성제약 용도를 위한 소마토스타틴 유사체를 함유하는 조성물
EP4034176A1 (en) Radiolabelled grpr-antagonist for use as theragnostic
JP7802851B2 (ja) 放射性標識されたｇｐｒｐアンタゴニスト及び界面活性剤を含む医薬組成物
US20250313579A1 (en) Ligand compounds comprising a chelating group as a bridging group
RU2839656C1 (ru) Стабильная концентрированная радиофармацевтическая композиция
RU2855011C1 (ru) Способы мечения радиоактивными изотопами антагонистов grpr и наборы на для их осуществления

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000